Inclusion Criteria:

          1. Biopsy proven HER2 negative metastatic breast cancer (dose escalation portion and MTD
             expansion portion) or advanced solid tumor (dose escalation portion).

          2. ASS deficiency (defined as <50% ASS expression) demonstrated on tissue specimen by
             Immunohistochemistry (IHC). Cytology and fine need aspirate specimens are not
             acceptable for ASS testing.

          3. Unresectable disease or subject refused surgery.

          4. Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).

          5. Failed available therapy known to confer clinical benefit but no more than 4 prior
             lines of chemotherapy for metastatic disease.

          6. Time to treatment failure from doxorubicin containing regimen ≥ 12 months if
             previously treated with doxorubicin.

          7. Age ≥ 18 years.

          8. ECOG performance status of 0 - 2. -

        Exclusion Criteria:

          1. Serious infection requiring treatment with systemically administered antibiotics at
             the time of study entrance, or an infection requiring systemic antibiotic therapy
             within 7 days prior to the first dose of study treatment.

          2. Prior epirubicin exposure of > 600 mg/m2.

          3. Pregnancy or lactation.

          4. Expected non-compliance.

          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure (New York Heart Association Class III
             or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit
             compliance with study requirements.

          6. Subjects who have had any anticancer treatment prior to entering the study and have
             not recovered to baseline (except alopecia) or ≤ Grade 1 AEs, or deemed irreversible
             from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a
             safety risk by the Sponsor and Investigator may be allowed upon agreement with both.

          7. Subjects with history of another primary cancer, including co-existent second
             malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b)
             curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no
             known active disease present in the opinion of the Investigator will not affect
             subject outcome in the setting of breast cancer diagnosis.

          8. Subjects who had been treated with ADI-PEG 20 previously.